Short description
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization
Description
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps, as well as animal rabies vaccine for canines. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot, and mouth disease), of which the EV71 vaccine is currently in Phase III clinical trials, pneumococcal conjugate, pneumococcal polysaccharides, and rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines.
Last funding
Nopepepe
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Beijing, Beijing, China, Asia
Founded on
January 1, 2001
Exited on
November 3, 2003
Went public on
November 3, 2003
Delisted on
June 26, 2017
Stock symbol
SVA
Non-profit?
No
Acquired?
No
Employees count
501-1000
Revenue range
$56378 - 90123
Sign in for full access
Investors
No Way, Absolutely Noaccess, Blurry Noaccess
Sign in for full access
Founders
Weidong Yin
Funding rounds count
3
Portfolio organisations count
Nopepepe, No Way
Sign in for full access
Lead investments count
1
Exits count
Noaccessforu, Absolutely Noaccess
Sign in for full access
IPO exits count
1